Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2022 and 2023.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2023
EGEIRO PHARMA from Charleroi, company number BE0684906013, closed financial year 2023 with a result of € -1.6 million after tax. For that financial year EGEIRO PHARMA recorded revenue of € 117,839 and equity of € 6 million. Compared with financial year 2022, the result moved from € -2.3 million to € -1.6 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 8, 2024.
€ 6 million
▼ 20% vs 2022
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.6 million
▲ 32 % less loss than in 2022
Profit after tax over the fiscal year.
€ 1.1 million
▼ 64% vs 2022
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -5.8 million.
People and assets in 2023
7.5
▼ 4.4 vs 2022
Average over the fiscal year, from the social balance sheet.
€ 770,425
▼ 31% vs 2022
€ 102,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,870
▼ 66% vs 2022
Book value of vehicles, furniture and equipment.
Debts at end 2023
€ 1.2 million
▲ 11% vs 2022
€ 159,267 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 131,615
▼ 3% vs 2022
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 30 days on average.
€ 100,527
▼ 58% vs 2022
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2021 | 2022 | 2023 | Change 2022 → 2023 | |
|---|---|---|---|---|
| Revenue | € 12,348 | € 94,037 | € 117,839 | ▲ 25% |
| Profit after taxes | € -1,340,850 | € -2,315,628 | € -1,570,708 | ▲ € 744,920 |
| Equity | € 9,647,627 | € 7,521,135 | € 6,049,198 | ▼ 20% |
| Total debts | € 1,803,836 | € 1,980,651 | € 1,484,992 | ▼ 25% |
| Cash | € 5,631,418 | € 3,185,671 | € 1,147,082 | ▼ 64% |
| Retained profit | € -1,956,667 | € -4,272,294 | € -5,843,002 | ▼ € 1.6 million |
| Bank debt | € 1,001,623 | € 1,048,090 | € 1,159,867 | ▲ 11% |
| Balance sheet total | € 11,451,463 | € 9,501,785 | € 7,534,190 | ▼ 21% |
| Employees (FTE) | 7.7 | 11.9 | 7.5 | ▼ 4.4 |
Key figures of EGEIRO PHARMA, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.
What happened to EGEIRO PHARMA?
What happened at EGEIRO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
EGEIRO PHARMA is active according to the CBE. Legal situation: Opening faillissement.
- Simon WHEELER stepped down as director. NBB
- NESYA GORIS LIFESCIENCES CONSULTING BV stepped down as director. NBB
- New annual accounts for financial year 2023: loss of € 1.6 million. filed late Source: NBB ↗
- ENRICO BASTIANELLI SRL stepped down as director. NBB
- CAPITAL ET CROISSANCE SCRL stepped down as director. NBB
- Julie WINAND stepped down as director. NBB
- Simon WHEELER became a director. NBB
- NESYA GORIS LIFESCIENCES CONSULTING BV became a director. NBB
In short
From € 1.3 million loss in 2021 to € 1.6 million loss in 2023.
Pays suppliers within 30 days on average.
Management
The stake of LUXEMBOURG DEVELOPPEMENT EUROPE DEUX, INVESTSUD TECH, ENRICO BASTIANELLI sprl comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EGEIRO PHARMAThe shares are held by LUXEMBOURG DEVELOPPEMENT EUROPE DEUX (11.4%), INVESTSUD TECH (11.1%) and ENRICO BASTIANELLI sprl (5%). It owns 100% of THERAVET US A, INC (Corporation) itself.
Directors
According to the 2023 annual accounts
since 2017 · until 2023
Simon WHEELER
Director
since 2021 · until 2026
Director · represented by MATHIEU JEAN-PHILIPPE
Also active at: CONCEPTEXPO GROUP, COLONA, MEGAFORM, SUPERPLASTIC, SOCIETE COMMERCIALE ET INDUSTRIELLE, BAUWENS ROGER, SOGECAM, HORUS SOFTWARE +29 more
since 2017 · until 2023
NESYA GORIS LIFESCIENCES CONSULTING BV
Director · represented by Nesya GORIS
since 2021 · until 2026
Director · represented by BASTIANELLI ENRICO
Also active at: APAXEN, MitralShape, DERMANOVE
since 2017 · until 2024
Shareholders
Participations
THERAVET US A, INC (Corporation)
100%
Establishments
Establishment units
Physical locations of this company
Avenue Jean Mermoz 32 box 1
6041 Charleroi
Researchdreef 4
1070 Anderlecht
Active since 1 July 2018
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0684.906.013
- VAT number
- BE 0684.906.013
- Registered office
- Avenue Jean Mermoz 32 bus 1, 6041 Charleroi
- Names & denominations
- EGEIRO PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Opening faillissement
- Start date
- 22 November 2017
- Peppol
- Not registered
- Activities · NACE
Vervaardiging van andere anorganische chemische basisproducten